INCLIVA participa en un ensayo para determinar la dosis óptima de un anticuerpo en el tratamiento de la trombocitemia esencial y la mielofibrosis

by INCLIVA

El ensayo analiza un anticuerpo biespecífico frente a la Calreticulina mutada y el CD3 de los linfocitos para frenar estos trastornos hematológicos

Read more

Último paciente del estudio: Laminar Pharmaceuticals S.A. completa el reclutamiento para CLINGLIO, el ensayo clínico de fase 2b/3 de ácido idroxioleico (LAM561) en combinación con RT y TMZ para adultos con glioblastoma de nuevo diagnóstico

by Laminar Pharma

Laminar Pharmaceuticals S.A. se complace en anunciar que el reclutamiento de pacientes para el estudio CLINGLIO (NCT04250922) se ha cerrado después de que 140 pacientes adultos se hayan reclutado con...

Read more

Augustine Therapeutics raises eur 17 million in a series a first closing to advance lead candidate into clinical development in neurological diseases

by Asabys Partners

Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million...

Read more

ORYZON announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb trial in Borderline Personality Disorder, at the 37th ECNP annual conference

by Oryzon Genomics

Oryzon today announced that it will present final data from its Phase IIb PORTICO trial, which investigated the efficacy of vafidemstat in the treatment of Borderline Personality Disorder (BPD), as an...

Read more

Checkmate 8HW: first-line dual immunotherapy decreases the risk of disease progression, reduces symptoms and improves quality of life of patients with metastatic colorectal cancer subtype

by VHIO

The Checkmate 8HW phase III clinical trial is evaluating the combination of nivolumab plus ipilimumab, two immunotherapy drugs, against chemotherapy as first-line treatment in patients with a subtype ...

Read more

Científicos españoles participan en la decisión de la FDA de adelantar la aprobación de fármacos en ensayos clínicos para pacientes con mieloma múltiple

by CIMA - Centro de Investigación Médica Aplicada

Esta resolución afectará, de momento, a personas con enfermedad mínima residual negativa con este tipo de cáncer hematológico y facilitará su acceso a nuevos fármacos y tratamientos

Read more

Nanomol Technologies se convierte en laboratorio farmacéutico acreditado por la Agencia Española de Medicamentos y Productos Sanitarios

by Nanomol Technologies
  • 2 years ago

Nanomol Technologies es un proveedor de tecnología de sistemas de liberación controlada de fármacos y de nanoformulación de principios activos, y un laboratorio de referencia en el análisis de pa...

Read more

ORYZON receives 'Decision to grant' for two important patents for vafidemstat in Japan

by Oryzon Genomics

It has been announced today that it they has received “Decision to grant” communications from the Japanese Patent Office (JPO) for two Japanese patent applications related to vafidemstat, Oryzon...

Read more

Future of metabolomics in R&D

by Rubió

Metabolomics is a rapidly advancing field in biomedical research and has gained significant attention in recent years. This promising discipline involves the comprehensive analysis of metabolites in b...

Read more

La nueva ronda de 1.3 millones € para Viva in Vitro le permite superar los 3 M € de inversión para luchar contra la sepsis e impulsar la medicina personalizada.

by Viva In Vitro Diagnostics

El trabajo de Viva in Vitro le ha llevado a ser pionero en el campo de la lucha contra la sepsis, donde gracias a su equipo a la vanguardia en investigación científica en las áreas de biología mol...

Read more

Mutua Madrileña Foundation supports a Bellvitge project that will promote the clinical use of bioartificial kidneys

by IDIBELL - Institut d’Investigació Biomèdica de Bellvitge

The study, led by Dr. Miguel Hueso, will help create alternatives to organ donation and dialysis for the treatment of chronic diseases, and the development of new drugs.

Read more

VHIO-led FRESCO-2 phase 3 trial leads to approval from EMA for the first novel targeted therapy for metastatic colorectal cancer in over a decade

by VHIO

Announced by the European Medicines Agency (EMA) last month, June 21, the highly selective and potent VEGFR inhibitor fruquintinib has been approved as the first novel targeted therapy in the EU for m...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Telum Therapeutics Secures €18 Million...

by Telum Therapeutics

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream